The patent application WO2015083071 describes a novel class of dual orexin receptor antagonists for the treatment of sleep disorders [1]. Daridorexant is a medication that falls under this category [1]. Orexin receptors, specifically OX1R and OX2R, play a crucial role in regulating wakefulness [1]. By blocking these receptors, daridorexant is designed to reduce the signaling pathways that promote wakefulness, thereby facilitating sleep [1].
What are the potential uses for daridorexant?
Daridorexant is being investigated for the treatment of insomnia [1]. Insomnia is characterized by difficulty falling asleep or staying asleep, leading to impaired daytime functioning [1]. As a dual orexin receptor antagonist, daridorexant aims to address the underlying neurobiology of wakefulness that can be dysregulated in individuals with insomnia [1].
How does daridorexant work to treat insomnia?
Daridorexant functions by binding to and inhibiting both the orexin 1 receptor (OX1R) and the orexin 2 receptor (OX2R) in the brain [1]. Orexins are neuropeptides that promote wakefulness. By blocking the action of orexins at their receptors, daridorexant reduces the excitatory signaling that maintains wakefulness, helping to initiate and maintain sleep [1].
When might daridorexant become available?
The availability of daridorexant depends on regulatory approvals following clinical trials. While patent applications indicate the invention of the compound and its potential use, the timeline for market entry is determined by the drug development and approval process [1].
What is the patent status of WO2015083071?
WO2015083071 is a patent application that was published on June 25, 2015, detailing the chemical structures and uses of dual orexin receptor antagonists, including compounds like daridorexant [1]. Patent applications outline inventions and their potential scope, and they can lead to granted patents that provide market exclusivity [1]. Information on the current patent landscape for daridorexant and related compounds can be found on DrugPatentWatch.com [2].
Who is developing daridorexant?
Daridorexant is being developed by Idorsia Pharmaceuticals [3]. Idorsia has advanced daridorexant through clinical development for the treatment of insomnia [3].
How does daridorexant compare to other insomnia treatments?
Daridorexant represents a different therapeutic class than traditional hypnotics such as benzodiazepines or non-benzodiazepine receptor agonists (e.g., zolpidem), which act on GABA receptors [1]. Unlike treatments that broadly sedate the central nervous system, daridorexant specifically targets the orexin system that promotes wakefulness [1]. This mechanism is thought to offer a more targeted approach to managing insomnia without necessarily causing the same degree of sedation or potential for dependence associated with some older medications [1].
What are the potential risks or side effects of daridorexant?
As with any medication, daridorexant may have side effects. Clinical trial data would provide specific information on adverse events observed during testing. Generally, medications affecting neurotransmitter systems can have varied effects on individuals [1]. Patients should consult with their healthcare provider for a full understanding of potential risks and side effects.
Can daridorexant be used for other sleep disorders?
While WO2015083071 focuses on sleep disorders generally, daridorexant's primary development focus has been on insomnia [1, 3]. The orexin system is involved in various aspects of sleep-wake regulation, but specific indications for other sleep disorders would require separate clinical investigation and regulatory approval.
---
Sources:
[1] WO2015083071 (World Intellectual Property Organization)
[2] https://drugpatentwatch.com/
[3] Idorsia Pharmaceuticals